Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Corixa Corporation GlaxoSmithKline |
---|---|
Information provided by: | Corixa Corporation |
ClinicalTrials.gov Identifier: | NCT00022958 |
The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody.
Condition | Intervention |
---|---|
Non-Hodgkin's Lymphoma |
Drug: Iodine-131 Anti-B1 Antibody |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Study ID Numbers: | CP-98-020 |
Study First Received: | August 16, 2001 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00022958 |
Health Authority: | United States: Food and Drug Administration |
Non-Hodgkin's Lymphoma Radioimmunotherapy Monoclonal Antibody Corixa Bexxar |
Anti-B1 Antibody Tositumomab Iodine -131 Anti-B1 Antibody Iodine I 131 Tositumomab |
Antibodies, Monoclonal Lymphatic Diseases Antibodies Immunoproliferative Disorders Iodine-131 anti-B1 antibody Lymphoma, small cleaved-cell, diffuse |
Iodine Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma Immunoglobulins |
Anti-Infective Agents Neoplasms by Histologic Type Immune System Diseases Immunologic Factors Antineoplastic Agents Growth Substances Physiological Effects of Drugs |
Trace Elements Pharmacologic Actions Anti-Infective Agents, Local Neoplasms Therapeutic Uses Micronutrients |